Welcome to our dedicated page for TriSalus Life Sciences news (Ticker: TLSI), a resource for investors and traders seeking the latest updates and insights on TriSalus Life Sciences stock.
TriSalus Life Sciences, Inc. (symbol: TLSI) is engaged in the research, development, and sale of groundbreaking drug delivery technology and immuno-oncology therapeutics. The company's mission is to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers.
Core Business: TriSalus focuses on two main product lines: the Pressure Enabled Drug Delivery (PEDD) infusion systems and an investigational agent called SD-101 (nelitolimod). The PEDD infusion systems are already in use and are designed to enhance the delivery of therapeutic agents to tumors. The investigational agent SD-101 aims to stimulate the immune system to better combat hepatocellular cancer, pancreatic cancer, and other solid tumors located in the liver.
Recent Achievements: One of the company's major advancements is the development of TriNav, a new therapy delivery device that incorporates SmartValve technology to optimize the PEDD approach. This innovative device has the potential to significantly improve treatment efficacy and patient outcomes.
Current Projects: TriSalus is actively involved in clinical trials to evaluate the effectiveness of SD-101 in various types of liver and pancreatic cancers. These trials are crucial for securing future regulatory approvals and bringing new treatments to market.
Financial Condition: While detailed financial information is not provided, the company's ongoing research and development initiatives, coupled with its active market presence, indicate a robust commitment to transforming cancer treatment.
Partnerships: TriSalus collaborates with leading academic and medical institutions to advance its research and bring innovative therapies to patients. These partnerships are essential for the clinical validation and widespread adoption of its technologies.
Products:
- PEDD Infusion Systems: These systems enhance drug delivery to tumors, increasing the efficacy of cancer treatments.
- SD-101 (nelitolimod): An investigational agent designed to boost the immune system's response to liver and pancreatic cancers.
- TriNav: The latest innovation in therapy delivery devices, featuring SmartValve technology to improve drug delivery efficiency.
TriSalus Life Sciences (NASDAQ: TLSI) presented clinical data from its Phase 1b PERIO-02 trial at the ASCO 2024 Annual Meeting. The trial studies the hepatic arterial infusion (HAI) of nelitolimod using TriSalus's proprietary Pressure Enabled Drug Delivery (PEDD) technology in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The 4 mg dose showed promising results with all three patients achieving disease control, including one complete response, one partial response, and one stable disease. Follow-up is ongoing to determine the next steps. The PEDD method aims to improve drug delivery within tumor microenvironments, potentially enhancing treatment efficacy. Median progression-free survival for the 4 mg dose was over 120 days. The study also noted significant immune responses, including increased CD4 and CD8 T cells in liver tumors.
TriSalus Life Sciences (NASDAQ: TLSI), an oncology company, announced an exchange offer and consent solicitation for its various warrants. The initiative aims to simplify the capital structure and reduce the dilutive impact of these warrants. Holders of the Public Warrants, Private Placement Warrants, and Working Capital Warrants are offered to exchange their warrants for 0.30 shares of common stock per warrant. If adopted, the Warrant Amendment will require outstanding warrants to be exchanged at 0.27 shares per warrant. The offer involves up to 4,264,532 shares of common stock and seeks consents from warrant holders to amend the warrant agreements. The offer expires on June 25, 2024, and is managed by Oppenheimer & Co. Inc.
TriSalus Life Sciences (Nasdaq: TLSI) reported its Q1 2024 financial results, highlighting a 116% year-over-year revenue increase to $6.5 million, driven by the TriNav® Infusion System. The gross margin improved to 85%, up from 78% in Q1 2023. Despite increased investments leading to an operating loss of $11.7 million and a net loss of $13.2 million, the company secured up to $50 million in debt financing with OrbiMed. Additionally, TriSalus appointed Liselotte Hyveled to its Board of Directors. The company forecasts full-year sales growth to exceed 50%.
TriSalus Life Sciences, a Nasdaq-listed oncology company, appointed Liselotte Hyveled to its Board of Directors. Hyveled, an industry veteran with over two decades of experience in pharmaceutical research and development, will contribute to TriSalus' vision of pioneering innovative treatments for liver and pancreatic cancers. Her strategic insights and patient-centric approach will be important in shaping the company's growth trajectory and advancing its technology and therapeutic pipelines.
TriSalus Life Sciences, a Nasdaq-listed oncology company, will host a conference call on May 15, 2024, at 9:00 a.m. ET to discuss first-quarter financial results and provide a business update. The call will cover the period ending March 31, 2024, and will be webcast live on their investor relations website.
TriSalus Life Sciences has secured up to $50 million in debt financing with OrbiMed to support the growth of its TriNav® Infusion System. $25 million was funded initially, with an option for an additional $25 million based on revenue thresholds. The financing is expected to fuel strategic expansion, extending the cash runway through 2025.
FAQ
What is the current stock price of TriSalus Life Sciences (TLSI)?
What is the market cap of TriSalus Life Sciences (TLSI)?
What does TriSalus Life Sciences, Inc. do?
What are the main products of TriSalus Life Sciences?
What is TriNav?
What types of cancer does TriSalus target?
What is the purpose of SD-101 (nelitolimod)?
Is TriSalus involved in any clinical trials?
Who are TriSalus' partners?
How can I stay updated on TriSalus' latest news?
What is the significance of the PEDD infusion systems?